There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Caladrius Biosciences stock.
Will CLBS go up?
Caladrius Biosciences Inc (NASDAQ:CLBS) The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 9.00, with a high estimate of 10.00 and a low estimate of 8.00. The median estimate represents a +1,132.88% increase from the last price of 0.73.